Description

DM3-SMe is a maytansine derivative and a tubulin inhibitor, and is a cytotoxic moiety of antibody-drug conjugates (ADCs), which can be linked to antibody through disulfide bond or stable thioether bond. DM3-SMe shows highly cytotoxic activity in vitro with an IC50 of 0.0011 nM[1][2].–Applications-Cancer-programmed cell death-Formula-C38H54ClN3O10S2-Citation–References-[1]Chen H, et al. Tubulin Inhibitor-Based Antibody-Drug Conjugates for Cancer Therapy. Molecules. 2017 Aug 1;22(8).|[2]Yuliang Zhaoet al. Biomedical Nanomaterials. 2016-‎Science.-CASNumber-796073-70-6-MolecularWeight-812.43-Compound Purity–SMILES-C[C@]12[C@H]([C@@H]([C@](O3)([H])C[C@]([C@](/C=C/C=C(C)/CC4=CC(N(C)C(C[C@]2([H])OC([C@H](C)N(C)C(CCC(C)SSC)=O)=O)=O)=C(C(OC)=C4)Cl)([H])OC)(NC3=O)O)C)O1-Research_Area-Cancer-Solubility-10 mM in DMSO-Target-ADC Cytotoxin;Microtubule/Tubulin-Isoform-Maytansinoids-Pathway-Antibody-drug Conjugate/ADC Related;Cell Cycle/DNA Damage;Cytoskeleton-MCE Product type-ADC Related